Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry
- PMID: 29576597
- DOI: 10.1253/circj.CJ-17-1128
Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry
Abstract
Background: Venous thromboembolism (VTE) has a long-term risk of recurrence, which can be prevented by anticoagulation therapy.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic VTE between January 2010 and August 2014. The entire cohort was divided into the transient risk (n=855, 28%), unprovoked (n=1,477, 49%), and cancer groups (n=695, 23%). The rate of anticoagulation discontinuation was highest in the cancer group (transient risk: 37.3% vs. unprovoked: 21.4% vs. cancer: 43.5% at 1 year, P<0.001). The cumulative 5-year incidences of recurrent VTE, major bleeding and all-cause death were highest in the cancer group (recurrent VTE: 7.9% vs. 9.3% vs. 17.7%, P<0.001; major bleeding: 9.0% vs. 9.4% vs. 26.6%, P<0.001; and all-cause death: 17.4% vs. 15.3% vs. 73.1%, P<0.001). After discontinuation of anticoagulation therapy, the cumulative 3-year incidence of recurrent VTE was lowest in the transient risk group (transient risk: 6.1% vs. unprovoked: 15.3% vs. cancer: 13.2%, P=0.001). The cumulative 3-year incidence of recurrent VTE beyond 1 year was lower in patients on anticoagulation than in patients off anticoagulation at 1 year in the unprovoked group (on: 3.7% vs. off: 12.2%, P<0.001), but not in the transient risk and cancer groups (respectively, 1.6% vs. 2.5%, P=0.30; 5.6% vs. 8.6%, P=0.44).
Conclusions: The duration of anticoagulation therapy varied widely in discordance with current guideline recommendations. Optimal duration of anticoagulation therapy should be defined according to the risk of recurrent VTE and bleeding as well as death.
Keywords: Anticoagulants; Bleeding; Mortality; Recurrence; Venous thromboembolism.
Similar articles
-
Cancer-Associated Venous Thromboembolism in the Real World - From the COMMAND VTE Registry.Circ J. 2019 Oct 25;83(11):2271-2281. doi: 10.1253/circj.CJ-19-0515. Epub 2019 Sep 20. Circ J. 2019. PMID: 31548438
-
Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants.Eur J Intern Med. 2023 Dec;118:59-72. doi: 10.1016/j.ejim.2023.08.007. Epub 2023 Aug 11. Eur J Intern Med. 2023. PMID: 37574348
-
Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry.Thromb Haemost. 2019 Sep;119(9):1498-1507. doi: 10.1055/s-0039-1692425. Epub 2019 Jun 23. Thromb Haemost. 2019. PMID: 31230344
-
Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.Thromb Res. 2014 Sep;134(3):627-32. doi: 10.1016/j.thromres.2014.07.001. Epub 2014 Jul 10. Thromb Res. 2014. PMID: 25047174 Review.
-
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.Ann Intern Med. 2010 May 4;152(9):578-89. doi: 10.7326/0003-4819-152-9-201005040-00008. Ann Intern Med. 2010. PMID: 20439576 Review.
Cited by
-
Real-world Data on Treatment Patterns and Bleeding in Cancer-associated Thrombosis: Data from the TROLL Registry.TH Open. 2024 Mar 26;8(1):e132-e140. doi: 10.1055/s-0044-1782219. eCollection 2024 Jan. TH Open. 2024. PMID: 38532938 Free PMC article.
-
Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients.J Clin Med. 2023 Oct 9;12(19):6427. doi: 10.3390/jcm12196427. J Clin Med. 2023. PMID: 37835070 Free PMC article.
-
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study.Thromb J. 2023 Aug 21;21(1):88. doi: 10.1186/s12959-023-00528-w. Thromb J. 2023. PMID: 37599351 Free PMC article.
-
Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.Res Pract Thromb Haemost. 2023 Mar 10;7(2):100115. doi: 10.1016/j.rpth.2023.100115. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 37063761 Free PMC article.
-
D-Dimer beyond Diagnosis of Pulmonary Embolism: Its Implication for Long-Term Prognosis in Cardio-Oncology Era.J Pers Med. 2023 Jan 27;13(2):226. doi: 10.3390/jpm13020226. J Pers Med. 2023. PMID: 36836459 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical